| Literature DB >> 35005431 |
V Chandrakala1, Valmiki Aruna1, Gangadhara Angajala1.
Abstract
Over the past few years, nanotechnology has been attracting considerable research attention because of their outstanding mechanical, electromagnetic and optical properties. Nanotechnology is an interdisciplinary field comprising nanomaterials, nanoelectronics, and nanobiotechnology, as three areas which extensively overlap. The application of metal nanoparticles (MNPs) has drawn much attention offering significant advances, especially in the field of medicine by increasing the therapeutic index of drugs through site specificity preventing multidrug resistance and delivering therapeutic agents efficiently. Apart from drug delivery, some other applications of MNPs in medicine are also well known such as in vivo and in vitro diagnostics and production of enhanced biocompatible materials and nutraceuticals. The use of metallic nanoparticles for drug delivery systems has significant advantages, such as increased stability and half-life of drug carrier in circulation, required biodistribution, and passive or active targeting into the required target site. Green synthesis of MNPs is an emerging area in the field of bionanotechnology and provides economic and environmental benefits as an alternative to chemical and physical methods. Therefore, this review aims to provide up-to-date insights on the current challenges and perspectives of MNPs in drug delivery systems. The present review was mainly focused on the greener methods of metallic nanocarrier preparations and its surface modifications, applications of different MNPs like silver, gold, platinum, palladium, copper, zinc oxide, metal sulfide and nanometal organic frameworks in drug delivery systems. © Qatar University and Springer Nature Switzerland AG 2021.Entities:
Keywords: Drug carriers; Drug delivery; Metallic nanoparticles; Nanocarriers
Year: 2022 PMID: 35005431 PMCID: PMC8724657 DOI: 10.1007/s42247-021-00335-x
Source DB: PubMed Journal: Emergent Mater ISSN: 2522-5731
Fig. 1The size, shape, material, and surface of the nanoparticles
Fig. 2A Schematic representation of top-down and bottom-up approaches. B Various methods involved in the synthesis of nanoparticles
Fig. 3Advantages of targeted drug delivery system
Fig. 4Multifunctional MNP-based delivery systems for targeting, delivery, and imaging
Metal nanoparticles for cancer therapy approved by FDA or EMA and clinical trials
| Nanomaterial | Sponsor/company name | Indication/application | Clinical trial identifier |
|---|---|---|---|
| Iron oxide | Iron-based inorganic nanoparticles Magnablate I (University College London) | Prostate cancer | NCT02033447 (Ph 0) |
| Magnetic iron oxide NPs | MagProbeTM (University of New Mexico) | Detection of leukemia | NCT01411904 |
| Gold nanoparticle with iron oxide silica cell | NANOM (Ural Medical University) | Plasmonic photothermal and stem cell therapy of atherosclerosis | NCT01270139 (not applicable), NCT01436123 (Ph I) |
| Spherical gold nanoparticle | NU-0129 (Northwestern University) | Recurrent glioblastoma or gliosarcoma undergoing surgery | NCT03020017 (Ph 0) |
| Silver nanoparticle gel | SilvaSorb (Madigan Army Medical Center) | Anti-bacterial | NCT00659204 (Ph III) |
| Nanocrystalline silver | Acticoat | Pemphigus; pemphigoid | NCT02365675 (not applicable) |
| Adhesive doped with Zn oxide + Cu nanoparticles in a (5%/0.2% concentration) | Cu/Zn nanoparticles (University of Chile) | Dental varies | NCT03635138 (not applicable) |
| Zinc oxide nanoparticles | Zinc oxide nanoparticles | Foot dermatoses; dental caries | NCT04000386 (not applicable), NCT03478150 (not applicable) |
| Titanium dioxide nanoparticles | Cairo University | Denture stomatitis | NCT02950584 (Ph I) |
| Mixture of gold and silver nanoparticles | NanoCare Gold | Caries class II | NCT03669224 (not applicable) |
| Hafnium oxide nanoparticle | Nanobiotix | Prostate adenocarcinoma | NCT02805894 |
| Silver nanoparticle/calcium hydroxide | Cairo University | Postoperative pain | NCT03692286 (Ph IV), NCT04213716 (Ph II) |
Microbe-mediated nanoparticles
| Species | Type of microorganism | Mode | Metal | Size (nm) | Reference |
|---|---|---|---|---|---|
| Fungi | Extracellular | Ag Au | 60–80 20–40 | [ [ | |
| Fungi | Extracellular | Au CdS Zr | 20–40 5–20 3–11 | [ [ [ | |
| Bacteria | Extracellular | Au | 10–20 | [ | |
| Bacteria | Intra cellular and Extracellular | Ag | 50–100 | [ | |
| Bacteria | Extracellular | Ag | 200 | [ | |
| Bacteria | Intracellualar | Pd, Ag, Rh, Ni, Fe, Co, Pt, Li | - | [ | |
| Bacteria | Extracellular | Pd, Pt | 2–7 | [ | |
| Actinomycetes | Extracellular | Ag | 10 | [ | |
| Actinomycetes | Extracellular | Ag | 8–48 | [ | |
| Actinomycetes | Extracellular | Cu Au | - | [ [ | |
| Fungi | Extracellular | Ag | - | [ | |
| Fungi | Extracellular | Au | - | [ | |
| Yeast | Extracellular | Ag | 20–80 | [ | |
| Yeast | Extracellular | Ag | 2–10 | [ |
Plant-mediated greener nanoparticles
| Plant | Origin | Mode | Metal | Size (nm) | Reference |
|---|---|---|---|---|---|
| Leaves | Extracellular | Ag | 40–60 | [ | |
| Arial parts | Extracellular | Ag | 36 | [ | |
| Leaves | Extracellular | ZnO | 9–17.5 | [ | |
| Leaves | Extracellular | Pd | 2–14 | [ | |
| Leaves | Extracellular | ZnO | 40.9 | [ | |
| Leaves | Extracellular | Ag | 50–100 | [ | |
| Plant | Extracellular | CuO | - | [ |
Fig. 5Biosynthesis of MNPs
Fig. 6Role of secondary metabolites in the formation of MNPs
Fig. 7Schematic representation of drug administrative route using MNPs
AgNPs in anti-cancer therapy
| S. no | Material used | Activity/cell line | Reference |
|---|---|---|---|
| 1 | PVP-coated AgNPs | Acute myeloid leukemia (AML) cells | [ |
| 2 | AgNPs | Human liver (HepG2) cells | [ |
| 3 | AgNPs | Colon carcinoma Caco-2 cells | [ |
| 4 | AgNPs | Cytotoxic effect to MCF-7 breast cancer | [ |
| 5 | AgNPs | Colon cancer cells/ HCT116, Caco-2 and HT-29 | [ |
| 6 | AgPCA | HCT116 colorectal cells | [ |
| 7 | AgNPs-MTX | Lung cancer cell line (A-549) | [ |
| 8 | (MTX-GO/AgNPs) | Anti-cancer pharmacological activity | [ |
| 9 | Ag-NGO-DOX | HepG2 cancer cell line and HEK293 cell line | [ |
| 10 | DOX-AgNPs | Inhibition of the proliferation of cancer cells B16F10 | [ |
| 11 | IMAB-AgNPs | Cytotoxicity in MCF-7 cells | [ |
| 12 | AgNPs | Cytotoxicity and apoptosis in A2780 cells | [ |